Skip to content
Screener

Nuvation Bio NUVB Q4 2025 Annual earnings

Reported March 2, 2026 · After market close

Revenue$41.9MBeat by $4.1M
EPS-$0.11In line
Revenue estimate$37.8M
EPS estimate-$0.11

Next report

Nov 2, 2026 (in a month)
Revenue estimate$35.3M
EPS estimate-$0.12

Financials

Q4 2025

Income statement

See full
Revenue$41.9M+633%
Operating income-$34.0M+36.9%
Net income-$36.6M+26.0%
EPS (diluted)-$0.11—

Balance sheet

See full
Cash & equivalents$164.1M+359%
Total debt$57.4M+543%
Total equity$305.7M-34.1%
Total assets$594.8M+10.0%

Cash flow

See full
Operating cash flow-$29.7M+35.8%
CapEx-—
Free cash flow-$29.7M+35.8%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$3.07B+243%
Enterprise value$2.97B+241%
P/S48.8×-64.9×

Profitability

See full
Operating margin-338.7%-165pp
Net margin-325.3%-159pp
FCF margin-288.4%-130pp

Returns & leverage

See full
Return on equity-53.2%-17.7pp
Debt / equity0.2×+0.2×
Current ratio7×-2.1×

Segments

By product

See full
License$26.2M+358%
Product Revenue$15.7M—
Royalty Revenue$300.0K—

FAQ

When did Nuvation Bio report Q4 2025 earnings?
Nuvation Bio (NUVB) reported Q4 2025 earnings on March 2, 2026 after market close.
What were Nuvation Bio's Q4 2025 revenue and EPS?
Nuvation Bio reported revenue of $41.9M and eps of $-0.11 for Q4 2025.
Did Nuvation Bio beat estimates in Q4 2025?
Revenue beat the consensus estimate of $37.8M by $4.1M. EPS beat the consensus estimate of $-0.11 by $0.00.
How did Nuvation Bio's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 633.1% from $5.7M a year earlier and eps grew 26.7% from $-0.15.
Where can I find Nuvation Bio's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-085474) and the 10-K periodic report (0001193125-26-085584) directly on SEC EDGAR. The filing index links above go to sec.gov.